pharma · Non Small Cell Lung Cancer · Locally Advanced Solid Tumor · TNGX
Tango Therapeutics
Tango Therapeutics clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2017
- Employees
- 154
- Programs
- 7
- Drugs
- 2
- Patents
- 9
Tango Therapeutics projects
7 ClinicalTrials.gov programs sponsored by Tango Therapeutics.
Tango Therapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
S095035
Tango Therapeutics
MTAP-deleted Solid Tumors
1 trial -
TNG260
Tango Therapeutics
Non Small Cell Lung Cancer
1 trial -
TNG348
Tango Therapeutics
Breast Cancer
1 trial -
TNG456
Tango Therapeutics
Non Small Cell Lung Cancer
1 trial -
TNG462
Tango Therapeutics
Locally Advanced Solid Tumor
1 trial -
TNG908
Tango Therapeutics
Locally Advanced Solid Tumor
1 trial -
TNG908-C101
Tango Therapeutics
"Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors •MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM"
1 trial
Frequently asked questions
How many clinical projects does Tango Therapeutics have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.